Angelini Ventures has chosen Singapore as its first base in Asia, underlining the city-state’s role as a growing hub for biotech and healthtech innovation. The Rome-based corporate venture arm of Angelini Industries has opened a new regional office in the Central Business District to deepen collaboration with institutional partners and ecosystem leaders across the continent. The move is designed to accelerate the translation of life sciences and digital health innovation from Asia into real-world healthcare impact.
Angelini Ventures Deepens Global Footprint
The firm manages €300 million of evergreen capital focused on early-stage biotech, digital health and life sciences companies that can reshape the future of care. Since its launch in October 2022, Angelini Ventures has deployed around €125 million across 22 startups in Europe, North America and Asia. Its first investment in Asia came in May 2025, when it co-led a US$45 million Series B round in Singapore-based Nuevocor to advance gene therapy for genetic dilated cardiomyopathy.
Singapore Office and Intelligence Hub
The Singapore office will host the Angelini Ventures Global Intelligence Hub, which uses an AI-powered platform to track and analyze healthcare and life sciences startups worldwide. This proprietary system turns raw market data into actionable intelligence for the firm’s investment team and partners, helping identify high-potential ventures earlier and with greater precision. From Singapore, Angelini Ventures aims to extend this digital capability across the region, strengthening its pipeline of investable companies and supporting more data-driven decision-making in healthcare innovation.
Leadership to Anchor Asia Expansion
The regional office will be led by Managing Director and Country Head, Singapore, Elia Stupka, who brings more than two decades of executive experience in healthcare and life sciences. His background spans industry, academia and clinical environments, including an early role as a genomics researcher. In 1991, he worked with Nobel Laureate Dr Sydney Brenner to establish Singapore’s first genomics laboratory at the Institute of Molecular and Cell Biology, one of the country’s foundational research institutes.
Partnership with Enterprise Singapore
Angelini Ventures has entered a partnership with Enterprise Singapore to help local biomedical startups scale globally and improve access between Asian and European markets. Together they will launch Espresso Lab, a new venture boost program that offers selected Singapore-based biomedical startups tailored mentorship, bespoke business development support and access to critical industry data and insights. Supported by EnterpriseSG’s Startup SG initiative, the program is designed to strengthen commercial readiness, refine go-to-market strategies and connect emerging companies with smart capital, strategic partners and additional funding opportunities.
Collaboration with AI Singapore
In parallel, Angelini Ventures has signed a memorandum of understanding with AI Singapore to accelerate the commercialization of AI-driven biomedical solutions. The collaboration will include joint pitch events and other initiatives focused on healthcare and biotech ventures that integrate AI technologies into their products and services. By combining AI Singapore’s national talent pipeline and technical capabilities with Angelini Ventures’ sector focus and capital, the partners aim to turn more early-stage AI concepts into scalable healthcare innovations that deliver tangible patient outcomes.
Angelini Ventures’ decision to anchor its Asian presence in Singapore aligns the firm with one of the world’s most active centers for biomedical research, AI and innovation policy. Through its new regional office, AI-powered Intelligence Hub and partnerships with Enterprise Singapore and AI Singapore, the firm is positioning itself at the intersection of capital, technology and clinical impact. Backed by the industrial heritage of Angelini Industries and a growing global portfolio, the expansion signals a long-term commitment to making healthcare more accessible and patient-centric across Asia and beyond.